Introduction: No studies to date have assessed the efficacy/tolerability of degarelix in the relief of lower urinary tract symptoms (LUTS) secondary to prostate cancer (PrCa). Methods: Patients were randomised to degarelix 240/80 mg or goserelin 3.6 mg + bicalutamide flare protection (G+B); both treatments were administered for 3 months. The primary endpoint was change in International Prostate Symptom Score (IPSS) at week 12 compared with baseline. Results: This study was stopped early due to recruitment difficulties. 40 patients received treatment (degarelix n = 27; G+B n = 13); most had locally advanced disease and were highly symptomatic. Degarelix was non-inferior to G+B in reducing IPSS at week 12 in the full analysis set (p = 0.20); the significantly larger IPSS reduction in the per-protocol analysis (p = 0.04) was suggestive of superior reductions with degarelix. Significantly more degarelix patients had improved quality of life (IPSS question) at week 12 (85 vs. 46%; p = 0.01). Mean prostate size reductions at week 12 were 42 versus 25% for patients receiving degarelix versus G+B, respectively (p = 0.04; post hoc analysis). Most adverse events were mild/moderate; more degarelix patients experienced injection site reactions whereas more G+B patients had urinary tract infections/cystitis. Conclusion: In 40 men with predominantly locally advanced PrCa and highly symptomatic LUTS, degarelix was at least non-inferior to G+B in reducing IPSS at week 12.

Keywords:
Degarelix, Goserelin, Lower urinary tract symptoms, Prostate cancer
1.
Bright E, Abrams P: Diseases of the prostate. Rev Clin Gerontol 2010;20:10-19.
2.
Chapple CR, Roehrborn CG: A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006;49:651-658.
3.
Gammack JK: Lower urinary tract symptoms. Clin Geriatr Med 2010;26:249-260.
4.
Batista-Miranda JE, Molinuevo B, Pardo Y: Impact of lower urinary tract symptoms on quality of life using Functional Assessment Cancer Therapy scale. Urology 2007;69:285-288.
5.
Kumar V, Toussi H, Marr C, Hough C, Javle P: The benefits of radical prostatectomy beyond cancer control in symptomatic men with prostate cancer. BJU Int 2004;93:507-509.
6.
Lepor H, Kaci L: The impact of open radical retropubic prostatectomy on continence and lower urinary tract symptoms: a prospective assessment using validated self-administered outcome instruments. J Urol 2004;171:1216-1219.
7.
Gnanapragasam VJ, Kumar V, Langton D, Pickard RS, Leung HY: Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. Int J Urol 2006;13:711-715.
8.
Ponholzer A, Brossner C, Struhal G, Marszalek M, Madersbacher S: Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol 2006;24:325-330.
9.
Eckman MH, Ying J, Hertzfeld K, Kumar N, Barrett W: Longitudinal analysis of genitourinary and bowel symptoms in prostate cancer patients following brachytherapy. Am J Clin Oncol 2010;33:1-10.
10.
Laborde EE, McVary KT: Medical management of lower urinary tract symptoms. Rev Urol 2009;11:S19-S25.
11.
Crawford ED, Kavanagh BD: The role of α-blockers in the management of lower urinary tract symptoms in prostate cancer patients treated with radiation therapy. Am J Clin Oncol 2006;29:517-523.
12.
Labrie F, Belanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B: Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005;26:361-379.
13.
Van Poppel H, Nilsson S: Testosterone surge: rationale for gonadotropin-releasing hormone blockers? Urology 2008;71:1001-1006.
14.
Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schroder FH: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-1538.
15.
Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Crawford ED, Moul J, Jensen JK, Kold OT, Persson BE: Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836-842.
16.
Barry MJ, O'Leary MP: Advances in benign prostatic hyperplasia. The developmental and clinical utility of symptom scores. Urol Clin North Am 1995;22:299-307.
17.
Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK: A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180:1986-1992.
18.
Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker - results from a 1-year, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-813.
19.
Langenhuijsen JF, van Lin EN, Hoffmann AL, Spitters-Post I, Alfred WJ, Kaanders JH, Mulders PF: Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol 2011;29:52-57.
20.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B: Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. Urology 2006;68:116-120.
21.
Princivalle M, Broqua P, White R, Meyer J, Mayer G, Elliott L, Bjarnason K, Haigh R, Yea C: Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist. J Pharmacol Exp Ther 2007;320:1113-1118.
22.
Maudsley S, Davidson L, Pawson AJ, Chan R, Lopez de MR, Millar RP: Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-7544.
23.
Tang X, Yano T, Osuga Y, Matsumi H, Yano N, Xu J, Wada O, Koga K, Kugu K, Tsutsumi O, Schally AV, Taketani Y: Cellular mechanisms of growth inhibition of human epithelial ovarian cancer cell line by LH-releasing hormone antagonist Cetrorelix. J Clin Endocrinol Metab 2002;87:3721-3727.
24.
Lamharzi N, Halmos G, Jungwirth A, Schally AV: Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol 1998;13:429-435.
25.
Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, Vidaurre I, Szalontay L: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011;71:736-747.
26.
Porter AT, Ben-Josef E: Humoral mechanisms in prostate cancer: a role for FSH. Urol Oncol 2001;6:131-138.
27.
Garde SV, Sheth AR, Shah MG, Kulkarni SA: Prostate - an extrapituitary source of follicle-stimulating hormone: occurrence, localization, and de novo biosynthesis and its hormonal modulation in primates and rodents. Prostate 1991;18:271-287.
28.
Ben-Josef E, Yang SY, Ji TH, Bidart JM, Garde SV, Chopra DP, Porter AT, Tang DG: Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor. J Urol 1999;161:970-976.
29.
Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, Spera G, Gnessi L: Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175:2072-2077.
30.
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, Fromont G, Hai MT, Ghinea N: Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621-1630.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.